$DRI

DRI Maintained by Citigroup -- Price Target Raised to $248

Citigroup maintained a 'Buy' rating on Darden Restaurants (DRI), raising its price target to $248 from $245. The company's GF Value™ is $211.48, indicating a 1.1% undervaluation. DRI has a GF Score™ of 85/100, with strong profitability and valuation metrics. Insider activity shows significant selling, with $15.56M in sales over the last three months.

Original reporting
Published Sep 11, 2026, 6:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 12, 2026, 1:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$DRI
Bullish
medium confidence
Mentioned
$DRI
Relevance
5/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$DRIBullishMed
01

Why it matters

The rating upgrade aligns with a slight undervaluation but must be weighed against insider sell pressure.

02

Market read

Analyst target raise may prompt modest buying interest, though insider sales temper enthusiasm.

03

What to watch

Potential macro headwinds such as labor costs and inflation could limit upside.

Relevance 5/10Novelty 5/10Timing: today

Background

Darden Restaurants operates Olive Garden and LongHorn Steakhouse, with a market cap of ~$23.8B.

Company-level read

Ticker impact

$DRIBullishMedium confidence
Context

Citigroup maintained a Buy rating and raised Darden Restaurants' price target to $248, indicating a modest bullish outlook.

Expected impact

Potential modest upside of 2-3% as investors price in the higher target.

Evidence & confidence

The target raise is small and reflects confidence in continued recovery, but insider selling raises caution.

Market effects

Positive signal for the consumer cyclical restaurant sector.

U.S. market focus, limited regional effect.

Minimal global impact.

Counterpoint

Insider selling of $15.5M may signal downside risk despite the rating lift.

Key entities

  • Citigroup

    Maintained Buy rating and raised price target.

  • Darden Restaurants

    Subject of the rating update.

Related articles

$CMGMed

Baird Reshuffles Restaurant Ratings: Starbucks, Cava Top Picks as Chipotle, Domino's Cut to Neutral — BigGo Finance

Baird downgraded Chipotle (CMG) to Neutral, cutting its price target to $40, citing slower growth and higher reinvestment needs. Domino's (DPZ) and Black Rock Coffee Bar (BRCB) were also downgraded. Darden (DRI) was upgraded to Outperform with a $250 target. Baird favors Cava (CAVA), Starbucks (SBUX), and others with strong unit economics and growth potential.

$CMGMed

Baird downgrades Chipotle, Domino’s as restaurant divergence widens

Baird downgraded Chipotle (CMG), Domino's (DPZ), and Black Rock Coffee Bar (BRCB) to Neutral, citing slower growth and competitive pressures. It upgraded Darden (DRI) to Outperform, praising its strong fundamentals. Price targets were adjusted for each. Baird also initiated coverage of Brinker (EAT) and Jersey Mike's with Outperform ratings, and named Cava (CAVA), Brinker, Starbucks (SBUX), and Dutch Bros (BROS) as top picks.

$DRIHighAI 8/10

Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?

Darden Restaurants (DRI) reached a 52-week high in 2026, with fiscal sales surpassing $13 billion. Key brands like Olive Garden and LongHorn Steakhouse drove growth, with Q4 revenue up 13.7% YoY. Darden's stock rose 18% this year, supported by strong earnings and a new $1.5 billion share repurchase plan. The company provided optimistic 2027 guidance, including sales between $13.6B and $13.75B. Competitors like Domino's (DPZ) and Chipotle (CMG) faced weaker sales and stock declines.

$DRIMed

DRI Healthcare Announces Receipt of Put Price on EKTERLY

DRI Healthcare Trust (TSX: DHT.UN, DHT.U) said it received about US$178 million as the put price after exercising a contractual put option tied to its royalty participation right in EKTERLY. The put was exercised after Chiesi Group completed its acquisition of KalVista Pharmaceuticals. The transaction is now complete and the royalty right has terminated.